New platform solution for mAbs and difficult-to-express proteins

To better support the rising demand for development and manufacturing of more complex biologics particularly in US-based facilities, Oklahoma-based Cytovance Biologics and California-based Celltheon have partnered to deliver an improved, integrated solution that combines Celltheon’s CHO-K1-based cell line development platform and Cytovance’s fully integrated CDMO services.

Under the arrangement, Cytovance customers have access to Celltheon’s proprietary OmniCHO™ Platform for early-stage transient protein expression, the CELLTHEON SMART™ Platform for later stable clone development, as well as the optimized pGL™ Vectors and GOLDILOCKS™ transposase system.

Once the upstream development stage is completed, Celltheon’s customers will now be able to transfer their products into downstream development and take them all the way through cGMP manufacturing at Cytovance’s dedicated mammalian facilities, with scale up options of 1000 L and 2000 L bioreactors.

Axel Schleyer, CCO of Cytovance, commented, “We have seen first hand the improved timelines, manufacturability, and product yield that Celltheon’s expression technologies provide to their customers, and we are excited to now be able to welcome them and their novel therapeutics into our cGMP facilities. This partnership is also part of our strategic effort to expand our customer’s options for finding the perfect cell line for their target molecule, so they can reach the clinic and the market faster.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>